Ctexli (chenodiol) — United Healthcare
cerebrotendinous xanthomatosis (cholestanol storage disease)
Initial criteria
- Diagnosis of cerebrotendinous xanthomatosis (cholestanol storage disease)
Reauthorization criteria
- Documentation of positive clinical response to Ctexli therapy
Approval duration
12 months